✓ Translated by DotMD AI Clinical Council Source: Pharmaceutical statistics • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #37519010 ↗

Phase III Randomized Trial: Type-I-error rate inflation in mixed models for repeated measures caused by ambiguous or incomplete model specifications

Original Paper Title: “Type-I-error rate inflation in mixed models for repeated measures caused by ambiguous or incomplete model specifications”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • However, the results of this simulation study rather underestimate the true T1E rate inflation. In conclusion, imprecise MMRM specifications may lead to a substantial inflation of the T1E rate and can damage the ability to generate confirmatory evidence in pivotal clinical trials.
  • Study Design & Sample: Phase III Randomized Trial published in Pharmaceutical statistics (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Pharmaceutical statistics (2023), this phase iii randomized trial evaluating human clinical outcomes investigated: Pre-specification of the primary analysis model is a pre-requisite to control the family-wise type-I-error rate (T1E) at the intended level in confirmatory clinical trials. Key clinical takeaway: However, the results of this simulation study rather underestimate the true T1E rate inflation. In conclusion, imprecise MMRM specifications may lead to a substantial inflation of the T1E rate and can damage the ability to generate confirmatory evidence in pivotal clinical trials.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Pharmaceutical statistics, 2023-01-15; Phase III Randomized Trial; Rigor 88/100): However, the results of this simulation study rather underestimate the true T1E rate inflation. In conclusion, imprecise MMRM specifications may lead to a substantial inflation of the T1E rate and can damage the ability to generate confirmatory evidence in pivotal clinical trials.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: human-bite-accidental → Condition: swimmers-ear-otitis-externa →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 37519010: Phase III Randomized Trial: Type-I-error rate inflation in mixed models for repeated measures caused by ambiguous or incomplete model specifications

3 of 3 Free Questions Remaining